Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Neoadjuvant chemo for rectal cancer to be applied cautiously

Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution for advanced rectal cancer, and the latest British Journal of Cancer suggests concurrent chemoradiation with radiotherapy as the best option.

News image

fiogf49gjkf04

Neoadjuvant chemotherapy is a term originally used to describe the administration of chemotherapy preoperatively before surgery.

Neoadjuvant chemotherapy is induced chemotherapy to shrink or downstage a locally advanced tumor.

It thereby facilitates more effective local treatment with surgery or radiotherapy.

The method has been extended with more effective combinations of chemotherapy to reduce the risks of metastatic disease.

It seems logical that survival could be lengthened, or organ preservation rates increased in resectable tumors by neoadjuvant chemotherapy.

In rectal cancer neoadjuvant chemotherapy is being increasingly used in locally advanced and nonmetastatic unresectable tumors.

Randomized studies in advanced colorectal cancer show high response rates to combination cytotoxic therapy.

This evidence of efficacy coupled with the introduction of novel molecular targeted therapies have rekindled an interest in neoadjuvant chemotherapy.

Long waiting times for radiotherapy have also increased interest in delivering neoadjuvant chemotherapy in locally advanced rectal cancer.

In contrast, this enthusiasm is waning for sites such as head and neck, and nasopharynx cancer where traditionally neoadjuvant chemotherapy has been used.

The question arises whether neoadjuvant chemotherapy in rectal cancer a real advance or just history repeating itself.

Dr Glynne-Jones and colleagues from England explored the advantages and disadvantages of the separate approaches of chemotherapy.

The research team undertook a review of neoadjuvant, concurrent and consolidation chemotherapy in locally advanced rectal cancer.

The researchers drew on theoretical principles, preclinical studies and clinical experience both in rectal cancer and other disease sites.

The team found that neoadjuvant chemotherapy may improve outcome in terms of disease-free or overall survival in selected groups in some disease sites.

However, the researchers noted that this strategy has not been shown to be associated with better outcomes than postoperative adjuvant chemotherapy.

Neoadjuvant chemotherapy does not appear to enhance local control
British Journal of Cancer

In particular, the team highlighted that there is insufficient data in rectal cancer.

The evidence for benefit is strongest when neoadjuvant chemotherapy is administered before surgical resection.

In contrast, the data in favour of neoadjuvant chemotherapy before radiation or chemoradiation is inconclusive.

The team noted these findings despite the suggestion that response to induction chemotherapy can predict response to subsequent radiotherapy.

The observation that spectacular responses to chemotherapy before radical radiotherapy did not result in improved survival, was noted 25 years ago.

Multiple trials in head and neck cancer, nasopharyngeal cancer, and non-small-cell lung cancer, do no support the routine use of neoadjuvant chemotherapy.

The researchers also found that trials in small-cell lung cancer and cervical cancer do not support the routine use of neoadjuvant chemotherapy.

The trials identified did not advocate the use of neoadjuvant chemotherapy either as an alternative, or as additional benefit to chemoradiation.

The addition of neoadjuvant chemotherapy does not appear to enhance local control over concurrent chemoradiation or radiotherapy alone.

Dr Glynne-Jones' team concluded, “Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution, and only in the context of clinical trials.”

“The evidence base suggests that concurrent chemoradiation with early positioning of radiotherapy appears the best option for patients with locally advanced rectal cancer and in all disease sites where radiation is the primary local therapy.”

Br J Canc 2006: 94: 363-71
16 February 2006

Go to top of page Email this page Email this page to a colleague

 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us